Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 03, 2014 07:00 ET | Source: GlobeImmune, Inc.

GlobeImmune to Present at the Aegis Capital Corp. 2014 Healthcare Conference

LOUISVILLE, CO--(Marketwired - September 03, 2014) - GlobeImmune, Inc. (NASDAQ: GBIM) today announced that Timothy C. Rodell, M.D., Chief Executive Officer, will present at the Aegis Capital Corp....
August 15, 2014 16:30 ET | Source: GlobeImmune, Inc.

GlobeImmune Announces Second Quarter 2014 Financial Results

LOUISVILLE, CO--(Marketwired - August 15, 2014) - GlobeImmune, Inc. (NASDAQ: GBIM) today announced its second quarter 2014 corporate highlights and financial results. The net loss for the second...
July 02, 2012 17:58 ET | Source: GlobeImmune, Inc.

GlobeImmune Files Registration Statement for Proposed Initial Public Offering

LOUISVILLE, CO--(Marketwire - Jul 2, 2012) - GlobeImmune, Inc., today announced that it has publicly filed a registration statement with the U.S. Securities and Exchange Commission (SEC) relating...
June 27, 2012 09:15 ET | Source: GlobeImmune, Inc.

GlobeImmune's GI-4000 in Combination With Gemcitabine Following Surgery Shows Evidence of an Improvement in Survival in a Phase 2b Clinical Trial With Ras Mutation Positive Pancreas Cancer

BARCELONA, SPAIN--(Marketwire - Jun 27, 2012) - GlobeImmune, Inc., today announced that GI-4000 in combination with gemcitabine showed evidence of an improvement in overall survival for...
May 31, 2012 19:58 ET | Source: GlobeImmune, Inc.

Survival Data From GlobeImmune's Phase 2b Study in Patients With Resected Pancreas Cancer to Be Presented at ESMO 14th World Congress on Gastrointestinal Cancer

LOUISVILLE, CO--(Marketwire - May 31, 2012) - GlobeImmune, Inc., today announced that initial survival data from GI-4000-02, a Phase 2b study of the company's lead cancer product candidate,...
February 08, 2012 07:00 ET | Source: GlobeImmune, Inc.

GlobeImmune Initiates Phase 1 Clinical Trial of GI-6301 in Brachyury Expressing Cancers

LOUISVILLE, CO--(Marketwire - Feb 8, 2012) - GlobeImmune, Inc. today announced the initiation of a Phase 1 clinical trial to be conducted at the National Cancer Institute (NCI) to investigate the...
August 31, 2011 07:00 ET | Source: GlobeImmune, Inc.

GlobeImmune Promotes Jeffrey Dekker to Vice President of Finance

LOUISVILLE, CO--(Marketwire - Aug 31, 2011) - GlobeImmune Inc. announced today the promotion of Jeffrey Dekker to Vice President of Finance. Mr. Dekker previously served as Controller and Senior...
June 01, 2011 07:00 ET | Source: GlobeImmune, Inc.

GlobeImmune Reports Positive Results for Two Therapeutic Vaccines, GI-4000 and GI-6207

LOUISVILLE, CO--(Marketwire - Jun 1, 2011) - GlobeImmune Inc. today presented safety and immunogenicity data from two clinical studies of therapeutic vaccines based on the Company's Tarmogen®...
November 03, 2010 08:00 ET | Source: GlobeImmune, Inc.

GlobeImmune Receives Three Grants Under Federal Therapeutic Discovery Project Program

LOUISVILLE, CO--(Marketwire - November 3, 2010) - GlobeImmune Inc. today announced that the company has been awarded three grants totaling $733,438 under the federal Therapeutic Discovery...
October 30, 2010 11:55 ET | Source: GlobeImmune Inc.

UPDATE: Phase 2b Study Demonstrates GlobeImmune's GI-5005 HCV Therapeutic Vaccine Increases Sustained Virologic Response by 12 Percent in Patients Who Previously Failed Therapy With Standard of Care

LOUISVILLE, CO--(Marketwire - October 30, 2010) - GlobeImmune Inc. today announced additional data from the GI-5005-02 Phase 2b study demonstrating that GI-5005, the Company's investigational...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right